


U.S. National Library of Medicine National Center for Biotechnology Information **NLM Citation:** Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Fenofibrate. [Updated 2018 Dec 3]. **Bookshelf URL:** https://www.ncbi.nlm.nih.gov/books/



# Fenofibrate

Revised: December 3, 2018.

CASRN: 49562-28-9



# **Drug Levels and Effects**

## Summary of Use during Lactation

No relevant published information exists on the use of fenofibrate during breastfeeding. Because of a concern with disruption of infant lipid metabolism, fenofibrate is best avoided during breastfeeding. An alternate drug is preferred, especially while nursing a newborn or preterm infant. The manufacturer recommends that breastfeeding be avoided during fenofibrate therapy and for 5 days after the final dose.

## **Drug Levels**

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

**Disclaimer:** Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site .

### **Effects in Breastfed Infants**

Relevant published information was not found as of the revision date.

### **Effects on Lactation and Breastmilk**

Relevant published information was not found as of the revision date.

### **Alternate Drugs to Consider**

Cholestyramine, Colesevelam, Colestipol

# **Substance Identification**

#### **Substance Name**

Fenofibrate

#### **CAS Registry Number**

49562-28-9

#### **Drug Class**

Breast Feeding Lactation Anticholesteremic Agents Antilipemic Agents Fibric Acids